Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme

This article was originally published in The Pink Sheet Daily

Executive Summary

In exceptional cases, smaller and medium-sized companies might obtain PRIME designation in proof of principle stage, underscoring the expectation that they will particularly benefit from the program.

Advertisement

Related Content

First EU PRIME Designations Go To Biogen, ChemoCentryx, Kite, NovImmune
Many PRIME Applicants Are Missing Pediatric Investigation Plans
EMA's PRIME: Helpful But Not A Panacea
EMA, FDA Get Together On Drugs Eligible For PRIME And Breakthrough Designation
EMA's New PRIME Scheme Gets 18 Applications In First Month
European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes
A Faster Finish May Depend On A Better Start – EMA's PRIME Program
A Faster Finish May Depend On A Better Start – EMA's PRIME Program
'Different Animals With Different Purposes': Putting PRIME And Adaptive Pathways In Context

Topics

Advertisement
UsernamePublicRestriction

Register

PS079284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel